MicuRx Pharmaceuticals, Inc.

Target DRUG-RESISTANT bacteria infections Next generation of safe and effective antibiotics

Design, Discovery, and Development of Novel Drugs For Infectious Diseases and Unmet Medical Needs

Target DRUG-RESISTANT bacteria infections Next generation of safe and effective antibiotics

Design, Discovery, and Development of Novel Drugs For Infectious Diseases and Unmet Medical Needs

0102

SCIENTIFIC RESEARCH

MicuRx is a global biopharmaceutical company committed to discover, develop, and deliver innovative medicines that address unmet clinical needs. Founded in 2007, MicuRx’s headquarter is now located in Shanghai with branches in California, Hong Kong and Beijing.

PIPELINE

BETTER THERAPY THROUGH SUPERIOR MEDICINE 以良药求良效

Newsroom

More news

02 25 MicuRx Pharmaceutical : Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment 2025-02-25
01 04 MicuRx's Self-developed MRX-5 for NTM Infection Clinical Trial Application Approved 2025-01-04
12 21 FDA Grants Orphan Drug Designation to MicuRx’s MRX-5 for NTM Infections 2024-12-21
12 21 Online Launch of "Expert Consensus on the Use of Contezolid in the Treatment of Tuberculosis" Provides New Strategies for Drug-Resistant Tuberculosis Treatment 2024-12-21

About MicuRx
Scientific research
Pipeline
Newsroom
- Corporate news
Careers
Contact Us